

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. <i>Br J Urol</i> . 1998;81:801-10.
Abrams P, Kaplan S, De Koning G, H J, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. <i>Journal of Urology</i> . 2006;175:999-1004.
Abrams P, Malone-Lee J, Jacquetin B, Wyndaele JJ, Tammela T, Jonas U, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. <i>Drugs Aging</i> . 2001;18:551-60.
Abrams P, Swift S. Solifenacin is effective for the treatment of OAB dry patients: A pooled analysis. <i>European Urology</i> . 2005;48:483-7.
Akhila V, Pratapkumar. A comparison of transdermal and oral HRT for menopausal symptom control. <i>International journal of fertility and women's medicine</i> . 2006:64-9.
Alhasso A, Glazener C, M A, Pickard R, N'Dow J, M O. Adrenergic drugs for urinary incontinence in adults. <i>Cochrane Database of Systematic Reviews</i> . 2005.
Alhasso A, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. <i>Cochrane Database of Systematic Reviews</i> . 2006.
Allahdin S, McKinley CA, Mahmood TA. Tension free vaginal tape: a procedure for all ages. <i>Acta Obstet Gynecol Scand</i> . 2004;83:937-40.
Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> . 2006;17:502-11.
Andersson KE, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. <i>BJU International</i> . 2010;106:268-74.
Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. <i>Mayo Clinic proceedings Mayo Clinic</i> . 2001:358-63.
Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. <i>Urology</i> . 1997;90:6; discussion 7.
Armstrong RB, Dmochowski RR, Sand PK, MacDiarmid S. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: Combined results from two phase 4 controlled clinical trials. <i>International Urology and Nephrology</i> . 2007;39:1069-77.
Armstrong RB, Luber KM, Peters KM. Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. <i>International Urology and Nephrology</i> . 2005;37:247-52.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Arruda RM, Castro RA, Sousa GC, Sartori MG, Baracat EC, Girao MJ. Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. <i>Int Urogynecol J Pelvic Floor Dysfunct.</i> 2008;19:1055-61.
Atan A, Konety BR, Erickson JR, Yokoyama T, Kim DY, Chancellor MB. Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up. <i>Tech Urol.</i> 1999;5:67-70.
Bach P, Wormland RT, Mohring C, Goepel M. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity. <i>Neurourol Urodyn.</i> 2009;28:209-13.
Baigis-Smith J, Smith DA, Rose M, Newman DK. Managing urinary incontinence in community-residing elderly persons. <i>Gerontologist.</i> 1989 Apr;29(2):229-33.
Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. <i>Drugs Aging.</i> 2003;20:857-64.
Barber MD, Visco AG, Wyman JF, Fantl JA, Bump RC. Sexual function in women with urinary incontinence and pelvic organ prolapse. <i>Obstet Gynecol.</i> 2002;99:281-9.
Bodeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. <i>BMC Urol.</i> 2010;10:15.
Bödeker RH, Madersbacher H, Neumeister C, Zellner M. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. <i>BMC Urology.</i> 2010:15.
Bump RC, Norton PA, Zinner NR, Yalcin I. Mixed urinary incontinence symptoms: Urodynamic findings, incontinence severity, and treatment response. <i>Obstetrics and Gynecology.</i> 2003;102:76-83.
Burgio KL, Goode PS, Richter HE, Markland AD, Johnson TM, nd, et al. Combined behavioral and individualized drug therapy versus individualized drug therapy alone for urge urinary incontinence in women. <i>J Urol.</i> 2010;184:598-603.
Burgio KL, Kraus SR, Borello-France D, Chai TC, Kenton K, Goode PS, et al. The effects of drug and behavior therapy on urgency and voiding frequency. <i>International Urogynecology Journal and Pelvic Floor Dysfunction.</i> 2010;21:711-9.
Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, et al. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: A randomized trial. <i>Annals of Internal Medicine.</i> 2008;149:161-9.
Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: A randomized controlled trial. <i>Journal of the American Medical Association.</i> 1998;280:1995-2000.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Burgio KL, Locher JL, Roth DL, Goode PS. Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> . 2001;56:P46-P51.
Burgio KL, Whitehead WE, Engel BT. Urinary incontinence in the elderly. Bladder-sphincter biofeedback and toileting skills training. <i>Ann Intern Med</i> . 1985 Oct;103(4):507-15.
Capo JP, Lucente V, Forero-Schwanhaeuser S, He W. Efficacy and tolerability of solifenacin in patients aged (greater-than or equal to) 65 years with overactive bladder: Post-Hoc analysis of 2 open-label studies. <i>Postgraduate Medicine</i> . 2011;123:94-104.
Cardozo L, Hessdorfer E, Milani R, Arano P, Dewilde L, Slack M, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: Results from a randomized, double-blind, placebo-controlled, rising-dose trial. <i>BJU International</i> . 2008;102:1120-7.
Cardozo L, Khullar V, El-Tahtawy A, Guan Z, Malhotra B, Staskin D. Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. <i>BMC Urology</i> . 2010;10.
Cardozo L, Khullar V, Wang JT, Guan Z, Sand PK. Fesoterodine in patients with overactive bladder syndrome: Can the severity of baseline urgency urinary incontinence predict dosing requirement? <i>BJU International</i> . 2010;106:816-21.
Cardozo L, Lisec M, Millard R, Van Vierssen T, Kuzmin I, Drogendijk TE, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. <i>Journal of Urology</i> . 2004;172:1919-24.
Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women - A double-blind placebo-controlled study. <i>Journal of Obstetrics and Gynaecology</i> . 2001;21:383-5.
Cartwright R, Srikrishna S, Cardozo L, Robinson D. Patient-selected goals in overactive bladder: A placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. <i>BJU International</i> . 2011;107:70-6.
Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, et al. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> . 2007:919-29.
Chancellor M, Freedman S, Mitcheson HD, Antoci J, Primus G, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. <i>Clinical Drug Investigation</i> . 2000;19:83-91.
Chancellor MB, Kianifard F, Beamer E, Mongay L, Ebinger U, Hicks G, et al. A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. <i>Int J Clin Pract</i> . 2008;62:606-13.
Chancellor MB, Oefelein MG, Vasavada S. Obesity is associated with a more severe overactive bladder

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
disease state that is effectively treated with once-daily administration of trospium chloride extended release. <i>Neurourol Urodyn.</i> 2010;29:551-4.
Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. <i>Clinical Therapeutics.</i> 2008;30:1766-81.
Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Tolterodine Treatment Improves Storage Symptoms Suggestive of Overactive Bladder in Men Treated With (alpha)-Blockers. <i>European Urology.</i> 2009;56:534-43.
Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. <i>BJU Int.</i> 2005;95:993-1001.
Chapple CR, Abrams P. Comparison of darifenacin and oxybutynin in patients with overactive bladder: Assessment of ambulatory urodynamics and impact on salivary flow. <i>European Urology.</i> 2005;48:102-9.
Chapple CR, Arano P, Bosch JL, De R, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. <i>BJU Int.</i> 2004;93:71-7.
Chapple CR, Cardozo L, Steers WD, Govier FE. Solifenacin significantly improves all symptoms of overactive bladder syndrome. <i>International Journal of Clinical Practice.</i> 2006;60:959-66.
Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, et al. Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg. <i>European Urology.</i> 2007;52:1195-203.
Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an (alpha)-blocker: Effect of baseline prostate-specific antigen concentration. <i>BJU International.</i> 2010;106:1332-8.
Chapple CR, Martinez-Garcia R, Selvaggi L, Tooze-Hobson P, Warnack W, Drogendijk T, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. <i>European Urology.</i> 2005;48:464-70.
Chapple CR, Patroneva A, Raines SR. Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized, double-blind, placebo-controlled study (ZD0947IL/0004). <i>Eur Urol.</i> 2006;49:879-86.
Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. <i>BJU Int.</i> 2004;93:303-10.
Chapple CR, Van K, P E, Junemann KP, Wang JT, Brodsky M. Comparison of fesoterodine and tolterodine in patients with overactive bladder. <i>BJU Int.</i> 2008;102:1128-32.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Choo M, Lee JZ, Lee JB, Kim Y, Jung HC, Lee K, et al. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. <i>International Journal of Clinical Practice</i> . 2008;62:1675-83.
Choo MS, Doo CK, Lee KS. Satisfaction with tolterodine: Assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study). <i>International Journal of Clinical Practice</i> . 2008;62:191-6.
Choo MS, Song C, Kim JH, Choi JB, Lee JY, Chung BS, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: A prospective trial. <i>Journal of Urology</i> . 2005;174:201-4.
Chung SD, Chang HC, Chiu B, Liao CH, Kuo HC. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign prostatic hyperplasia. <i>Neurourol Urodyn</i> . 2011;30:568-71.
Cody J, Richardson K, Moehrer B, Hextall A, Glazener C, M A. Oestrogen therapy for urinary incontinence in post-menopausal women. <i>Cochrane Database of Systematic Reviews</i> . 2009.
Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. <i>Cochrane database of systematic reviews (Online)</i> . 2012;10:CD001405.
Collado S, Rubio-Briones J, Payas MP, Iborra J, Ramon-Borja JC, Narbon ES. Postprostatectomy established stress urinary incontinence treated with duloxetine. <i>Urology</i> . 2011;78:261-6.
Collas DM, Szonyi G, Ding YY, Malone-Lee JG. Oxybutynin with Bladder Retraining for Detrusor Instability in the Elderly - a Placebo Controlled Trial. <i>Age and Ageing</i> . 1994 January 1, 1994;23(suppl 2):P9-c-P.
Corcos J, Angulo JC, Garely AD, Carlsson M, Gong J, Guan Z. Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. <i>Current Medical Research and Opinion</i> . 2011;27:1059-65.
Cornu JN, Merlet B, Ciofu C, Mouly S, Peyrat L, Sebe P, et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. <i>Eur Urol</i> . 2011;59:148-54.
Cornu JN, Merlet B, Ciofu C, Mouly S, Peyrat L, Sebe P, et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. <i>Eur Urol</i> . 2011;59:148-54.
Couillard DR, Deckard-Janatpour KA, Stone AR. The vaginal wall sling: a compressive suspension procedure for recurrent incontinence in elderly patients. <i>Urology</i> . 1994 Feb;43(2):203-8.
Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). <i>Quality of Life Research</i> . 2005;14:849-55.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Cruz F, Guimaraes M, Silva C, Rio ME, Coimbra A, Reis M. Desensitization of bladder sensory fibers by intravesical capsaicin has long lasting clinical and urodynamic effects in patients with hyperactive or hypersensitive bladder dysfunction. <i>Journal of Urology</i> . 1997;157:585-9.
De R, Chandiramani V, Dasgupta P, Van P, Baert L, Fowler CJ. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. <i>J Urol</i> . 1997;158:2087-92.
Dessole S, Rubattu G, Ambrosini G, Gallo O, Capobianco G, Cherchi PL, et al. Efficacy of low-dose intravaginal estriol on urogenital aging in postmenopausal women. <i>Menopause</i> . 2004;11:49-56.
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. <i>Mayo Clinic Proceedings</i> . 2003;78:687-95.
Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. <i>BJU International</i> . 2007;100:107-10.
Dmochowski RR, Davila GW, Zinner NR, Gittelman MC, Saltzstein DR, Lyttle S, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. <i>The Journal of urology</i> . 2002;580-6.
Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. <i>Journal of Urology</i> . 2003;170:1259-63.
Dmochowski RR, Nitti V, Staskin D, Lubner K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. <i>World J Urol</i> . 2005;23:263-70.
Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F, et al. Randomized, Double-blind, Placebo-controlled Trial of Flexible-dose Fesoterodine in Subjects With Overactive Bladder. <i>Urology</i> . 2010;75:62-8.
Donath F, Braeter M, Feustel C. The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients. <i>Int J Clin Pharmacol Ther</i> . 2011;49:353-65.
Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 1999;10:283-9.
Durrant J, Snape J. Urinary incontinence in nursing homes for older people. <i>Age and Ageing</i> . 2003;32:12-8.
Dwyer P, Kelleher C, Young J, Haab F, Lheritier K, Ariely R, et al. Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study. <i>Neurourology and Urodynamics</i> . 2008;27:540-7.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, Roberts R. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: The IMPACT trial. <i>International Journal of Clinical Practice</i> . 2006;60:745-51.
Ellis N, Briggs R, Dowson D. The effect of acupuncture on nocturnal urinary frequency and incontinence. <i>Complement Ther Med</i> . 1990(4):16-7.
Erdinc A, Gurates B, Celik H, Polat A, Kumru S, Simsek M. The efficacy of venlafaxine in the treatment of women with stress urinary incontinence. <i>Archives of gynecology and obstetrics</i> . 2009:343-8.
Filocamo MT, Li M, Del P, Cecconi F, Villari D, Marzocco M, et al. Pharmacologic Treatment in Postprostatectomy Stress Urinary Incontinence. <i>European Urology</i> . 2007;51:1559-64.
Fonda D, woodward M, D'Astoli M, Chin W. The Continued Success Of Conservative Management For Established Urinary Incontinence In Older People. <i>Australian J Ageing</i> . 1994;13(1):12-6.
Fontanella U, Castiglioni M, Fonte A, Ostini F. Continence problems after radical prostatectomy: The medical treatment. <i>Archivio Italiano di Urologia e Andrologia</i> . 2001;73:157-9.
Franzen K, Johansson JE, Lauridsen I, Canelid J, Heiwall B, Nilsson K. Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. <i>Int Urogynecol J</i> . 2010;21:1517-24.
Freeman R, Hill S, Millard R, Slack M, Sutherst J. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. <i>Obstetrics and Gynecology</i> . 2003;102:605-11.
Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S, et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. <i>J Sex Med</i> . 2010;7:234-43.
Garely AD, Lucente V, Vapnek J, Smith N. Solifenacin for overactive bladder with incontinence: Symptom bother and health-related quality of life outcomes. <i>Annals of Pharmacotherapy</i> . 2007;41:391-9.
Gillon G, Stanton SL. Long-term follow-up of surgery for urinary incontinence in elderly women. <i>Br J Urol</i> . 1984 Oct;56(5):478-81.
Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. <i>Ditropan XL Study Group</i> . <i>Urology</i> . 1999;54:420-3.
Gomes T, Juurlink DN, Mamdani MM. Comparative adherence to oxybutynin or tolterodine among older patients. <i>European journal of clinical pharmacology</i> . 2012 Jan;68(1):97-9.
Goode PS, Burgio KL, Kraus SR, Kenton K, Litman HJ, Richter HE. Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women. <i>Int Urogynecol J</i> . 2011;22:327-34.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. <i>Journal of the American Geriatrics Society</i> . 2002;50:808-16.
Goode PS. Behavioral and drug therapy for urinary incontinence. <i>Urology</i> . 2004;63:58-64.
Gopal M, Sammel MD, Arya LA, Freeman EW, Lin H, Gracia C. Association of change in estradiol to lower urinary tract symptoms during the menopausal transition. <i>Obstetrics &amp; Gynecology</i> . 2008;112:1045-52.
Gordon D, Groutz A, Ascher-Landsberg J, Lessing JB, David MP, Razz O. Double-blind, placebo-controlled study of magnesium hydroxide for treatment of sensory urgency and detrusor instability: preliminary results. <i>British Journal of Obstetrics and Gynaecology</i> . 1998:667-9.
Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. <i>Obstetrics and Gynecology</i> . 2001;116:20.
Green SA, Alon A, Ianus J, McNaughton KS, Tozzi CA, Reiss TF. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. <i>The Journal of urology</i> . 2006;2535-40; discussion 40.
Griebing TL, Kraus SR, Richter HE, Glasser DB, Carlsson M. Tolterodine extended release is well tolerated in older subjects. <i>International Journal of Clinical Practice</i> . 2009;63:1198-204.
Grise P, Ruffion A, Denys P, Egon G, Chartier K. Efficacy and tolerability of botulinum toxin type a in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: Comparison of two doses. <i>European Urology</i> . 2010;58:759-66.
Haeusler G, Leitich H, van T, Kaider A, Tempfer CB. Drug therapy of urinary urge incontinence: a systematic review (Structured abstract). <i>Obstetrics and Gynecology</i> . 2002:1003-16.
Halaska M, Ralph G, Wiedemann A, Primus G, Ballering-Brühl B, Höfner K, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. <i>World journal of urology</i> . 2003:392-9.
Harari D, Igbedioh C. Restoring continence in frail older people living in the community: What factors influence successful treatment outcomes? <i>Age and Ageing</i> . 2009;38:228-33.
Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis (Structured abstract). <i>American Journal of Obstetrics and Gynecology</i> . 2001:56-61.
Hashim H, Malberg L, Graugaard-Jensen C, Abrams P. Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome. <i>Neurourology and Urodynamics</i> . 2009;28:40-6.
Hay-Smith J, Ellis G, Herbison GP. Which anticholinergic drug for overactive bladder symptoms in adults.



## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Cochrane Database of Systematic Reviews. 2005.
Hellberg D, Holmgren C, Lanner L, Nilsson S. The very obese woman and the very old woman: tension-free vaginal tape for the treatment of stress urinary incontinence. <i>Int Urogynecol J Pelvic Floor Dysfunct.</i> 2007;18:423-9.
Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. <i>Journal of the American Medical Association.</i> 2005;293(8):935-48.
Herschorn S, Becker D, Miller E, Thompson M, Forte L. Impact of a health education intervention in overactive bladder patients. <i>Can J Urol.</i> 2004;11:2430-7.
Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z. Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*. <i>Curr Med Res Opin.</i> 2008;24:3513-21.
Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, et al. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. <i>J Urol.</i> 2010;183:1892-8.
Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial. <i>BJU International.</i> 2010;105:58-66.
Hill S, Khullar V, Wyndaele JJ, Lheritier K, Darifenacin S, Group. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. <i>International Urogynecology Journal and Pelvic Floor Dysfunction.</i> 2006:239-47.
Ho CH, Chang TC, Lin HH, Liu SP, Huang KH, Yu HJ. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. <i>Journal of the Formosan Medical Association.</i> 2010;109:702-8.
Hofner K, Burkart M, Jacob G, Jonas U. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. <i>World J Urol.</i> 2007;25:627-33.
Hofner K, Burkart M, Jacob G, Jonas U. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. <i>World J Urol.</i> 2010;28:353-7.
Homma Y, Kawabe K. Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial. <i>World J Urol.</i> 2004;22:251-6.
Homma Y, Yamaguchi O. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. <i>International Journal</i>

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
of Urology. 2009;16:499-506.
Homma Y, Yamaguchi O. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. <i>Int J Urol.</i> 2008;15:986-91.
Homma Y, Yamaguchi T, Yamaguchi O. A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder. <i>Int J Urol.</i> 2008;15:809-15.
Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. <i>Journal of Obstetrics and Gynaecology Research.</i> 2011;37:1084-91.
Hurley DJ, Turner CL, Yalcin I, Viktrup L, Baygani SK. Duloxetine for the treatment of stress urinary incontinence in women: An integrated analysis of safety. <i>European Journal of Obstetrics Gynecology and Reproductive Biology.</i> 2006;125:120-8.
Ishiko O, Hirai K, Sumi T, Tatsuta I, Ogita S. Hormone replacement therapy plus pelvic floor muscle exercise for postmenopausal stress incontinence: A randomized, controlled trial. <i>Journal of Reproductive Medicine for the Obstetrician and Gynecologist.</i> 2001;46:213-20.
Jackson S, Shepherd A, Brookes S, Abrams P. The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind placebo-controlled trial. <i>British Journal of Obstetrics and Gynaecology.</i> 1999:711-8.
Jewart RD, Green J, Lu CJ, Cellar J, Tune LE. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. <i>American Journal of Geriatric Psychiatry.</i> 2005;13:324-8.
Johnson TM, nd, Burgio KL, Redden DT, Wright KC, Goode PS. Effects of behavioral and drug therapy on nocturia in older incontinent women. <i>J Am Geriatr Soc.</i> 2005;53:846-50.
Jonas U, Höfner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. <i>World journal of urology.</i> 1997:144-51.
Judge TG. The use of quinestradol in elderly incontinent women, a preliminary report. <i>Gerontologia clinica.</i> 1969;11(3):159-64.
Jumadilova Z, Varadharajan S, Girase P, Ollendorf DA. Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin. <i>American Journal of Health-System Pharmacy.</i> 2006;63:2357-64.
Kafri R, Langer R, Dvir Z, Katz-Leurer M. Rehabilitation vs drug therapy for urge urinary incontinence: Short-term outcome. <i>International Urogynecology Journal and Pelvic Floor Dysfunction.</i> 2007;18:407-11.
Kaplan SA, Goldfischer ER, Steers WD, Gittelman M, Andoh M, Forero-Schwannhaeuser S. Solifenacin treatment in men with overactive bladder: Effects on symptoms and patient-reported outcomes. <i>Aging Male.</i>

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
2010;13:100-7.
Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. <i>J Urol</i> . 2009;182:2825-30.
Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. <i>BJU Int</i> . 2008;102:1133-9.
Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial. <i>Journal of the American Medical Association</i> . 2006;296:2319-28.
Kaplan SA, Schneider T, Foote JE, Guan Z, Carlsson M, Gong J. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: A prospective, head-to-head, placebo-controlled trial. <i>BJU International</i> . 2011;107:1432-40.
Karademir K, Baykal K, Sen B, Senkul T, Iseri C, Erden D. A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. <i>Scand J Urol Nephrol</i> . 2005;39:230-3.
Karram MM, Togliola MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwannhaeuser S. Treatment With Solifenacin Increases Warning Time and Improves Symptoms of Overactive Bladder: Results From VENUS, a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Urology</i> . 2009;73:14-8.
Kay G, Crook T, Reveda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. <i>Eur Urol</i> . 2006;50:317-26.
Kelleher C, Cardozo L, Kobashi K, Lucente V. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2006;17:382-8.
Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: Pooled analysis of two open-label extension studies. <i>BJU International</i> . 2012;110(3):392-400.
Kelleher CJ, Reese PR, Pleil AM, Okano GJ. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. <i>American Journal of Managed Care</i> . 2002;8:S608-S15.
Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: Pooled data from two randomized trials. <i>BJU International</i> . 2008;102:56-61.
Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. <i>PLoS One</i> . 2011;6:e16718.
Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. <i>Urology</i> .

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
2004;64:269-75.
Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome. <i>Urology</i> . 2008;71:839-43.
Kim H, Yoshida H, Suzuki T. The effects of multidimensional exercise on functional decline, urinary incontinence, and fear of falling in community-dwelling elderly women with multiple symptoms of geriatric syndrome: a randomized controlled and 6-month follow-up trial. <i>Arch Gerontol Geriatr</i> . 2011;52:99-105.
Kim J, Lucioni A, Govier F, Kobashi K. Worse long-term surgical outcomes in elderly patients undergoing SPARC retropubic midurethral sling placement. <i>BJU Int</i> . 2011 Sep;108(5):708-12.
Kim SW, Song SH, Ku JH. Bladder training versus combination of propiverine with bladder training for female urinary frequency. A prospective, randomized, comparative study. <i>Gynecol Obstet Invest</i> . 2008;65:123-7.
Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> . 2005;16:337-44.
Klarskov N, Scholfield D, Soma K, Darekar A, Mills I, Lose G. Measurement of urethral closure function in women with stress urinary incontinence. <i>The Journal of urology</i> . 2009;2628-33; discussion 33.
Kraus SR, Ruiz-Cerda JL, Martire D, Wang JT, Wagg AS. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. <i>Urology</i> . 2010;76:1350-7.
Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the pharmacokinetics of solifenacin in men and women. <i>Int J Clin Pharmacol Ther</i> . 2005;43:227-38.
Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. <i>European Urology</i> . 2002;41:588-95.
Kreder KJ, Jr, Brubaker L, Mainprize T. Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. <i>BJU Int</i> . 2003;92:418-21.
Ku JH, Oh JG, Shin JW, Kim SW, Paick JS. Age is not a limiting factor for midurethral sling procedures in the elderly with urinary incontinence. <i>Gynecol Obstet Invest</i> 2006;61:194-9.
Kuo HC, Liu HT, Yang WC. Therapeutic Effect of Multiple Resiniferatoxin Intravesical Instillations in Patients With Refractory Detrusor Overactivity: A Randomized, Double-Blind, Placebo Controlled Study. <i>Journal of Urology</i> . 2006;176:641-5.
Landis JR, Kaplan S, Swift S, Versi E. Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. <i>The Journal of urology</i> . 2004:752-6.
Lee JG, Hong JY, Choo MS, Kwon HY, Chung DY, Lee KS, et al. Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder. <i>International Journal of Urology</i> . 2002;9:247-52.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. <i>BJU International</i> . 2004;94:817-20.
Lee YS, Choo MS, Lee JY, Oh SJ, Lee KS. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: A randomised, multicentre trial. <i>International Journal of Clinical Practice</i> . 2011;65:997-1004.
Leung HY, Yip SK, Cheon C, Liu YS, Lau J, Wong HK, et al. A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder. <i>BJU International</i> . 2002;90:375-80.
Liapis A, Bakas P, Georgantopoulou C, Creatsas G. The use of oestradiol therapy in postmenopausal women after TVT-O anti-incontinence surgery. <i>Maturitas</i> . 2010;66:101-6.
Lin AT, Sun MJ, Tai HL, Chuang YC, Huang ST, Wang N, et al. Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. <i>BMC Urol</i> . 2008;8:2.
Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. <i>J Urol</i> . 2005;173:493-8.
Long CY, Liu CM, Hsu SC, Chen YH, Wu CH, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. <i>Fertility and sterility</i> . 2006;155-60.
MacDiarmid SA, Anderson RU, Armstrong RB, Dmochowski RR. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: An analysis of data from 3 flexible dosing studies. <i>Journal of Urology</i> . 2005;174:1301-5.
Mahawong P, Chaiyaprasithi B, Soontrapa S, Tappayuthapijarn P. A role of intravesical capsaicin instillation in benign prostatic hyperplasia with overactive bladder symptoms: the first reported study in the literature. <i>J Med Assoc Thai</i> . 2007;90:2301-9.
Mallett V, Burks D, Garely AD, Smith N. Solifenacin treatment for overactive bladder in black patients: Patient-reported symptom bother and health-related quality of life outcomes. <i>Current Medical Research and Opinion</i> . 2007;23:821-31.
Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: Superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: A randomized controlled trial. <i>Journal of Urology</i> . 2001;165:1452-6.
Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. <i>J Am Geriatr Soc</i> . 2001;49:700-5.
Mariappan P, Alhasso A, Ballantyne Z, Grant A, N'Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review (Brief

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
record). <i>European Urology</i> . 2007;67-74.
Mariappan P, Alhasso A, Grant A, N'Dow J, M O. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. <i>Cochrane Database of Systematic Reviews</i> . 2005.
Martínez-García R, Abadías M, Arañó P, Perales L, Ruíz JL, Sust M, et al. Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study. <i>European Urology</i> . 2009;184-90.
Mattiasson A, Masala A, Morton R, Bolodeoku J. Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: Results from a randomized study. <i>BJU International</i> . 2010;105:1126-35.
Merchant RA, Li B, Yap KB, Ng TP. Use of drugs with anticholinergic effects and cognitive impairment in community-living older persons. <i>Age Ageing</i> . 2009;38:105-8.
Messelink EJ. Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist. <i>BJU Int</i> . 1999;83 Suppl 2:48-52.
Metello J, Nogueira B, Torgal M, Colaco J, Vieira A, Goncalves V, et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> . 2007;18:1021-5.
Michel MC, de la R, J J, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. <i>Eur Urol</i> . 2005;48:110-5.
Millard RJ, Halaska M. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. <i>Curr Med Res Opin</i> . 2006;22:41-8.
Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC, Duloxetine UISG. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. <i>BJU International</i> . 2004;311-8.
Millard RJ. Clinical Efficacy of Tolterodine with or Without a Simplified Pelvic Floor Exercise Regimen. <i>Neurourology and Urodynamics</i> . 2004;23:48-53.
Naglie G, Radomski SB, Brymer C, Mathiasen K, O'Rourke K, Tomlinson G. A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence. <i>J Urol</i> . 2002;167:586-90.
Newman DK. The MATRIX study: evaluating the data in older adults. <i>Director</i> . 2008;16:15-9.
Nilsson CG, Lukkari E, Haarala M, Kivela A, Hakonen T, Kiilholma P. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. <i>Neurourology and Urodynamics</i> . 1997;16:533-42.
Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. <i>BJU International</i> .

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
2006;97:1262-6.
Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. <i>J Urol.</i> 2007;178:2488-94.
Nitti VW, Rovner ES, Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. <i>BJU International.</i> 2010;105:1268-75.
Oelke M, Murgas S, Baumann I, Schnabel F, Michel MC. Efficacy of propiverine ER with or without alpha-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study. <i>World J Urol.</i> 2011;29:217-23.
Olshansky B, Ebinger U, Brum J, Egermark M, Viegas A, Rekeda L. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. <i>J Cardiovasc Pharmacol Ther.</i> 2008;13:241-51.
Oreskovic S, But I, Banovic M, Goldstajn MS. The efficacy and safety of solifenacin in patients with overactive bladder syndrome. <i>Collegium antropologicum.</i> 2012 Mar;36(1):243-8.
Ouslander JG, Cooper E, Godley D. Estrogen treatment for incontinence in frail older women. <i>J Am Geriatr Soc.</i> 1999;47:1383-4.
Ouslander JG, Greendale GA, Uman G, Lee C, Paul W, Schnelle J. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. <i>J Am Geriatr Soc.</i> 2001;49:803-7.
Ouslander JG, Griffiths P, McConnell E, Riolo L, Schnelle J. Functional Incidental Training: applicability and feasibility in the Veterans Affairs nursing home patient population. <i>J Am Med Dir Assoc.</i> 2005;6:121-7.
Ouslander JG, Griffiths PC, McConnell E, Riolo L, Kutner M, Schnelle J. Functional incidental training: A randomized, controlled, crossover trial in Veterans Affairs nursing homes. <i>Journal of the American Geriatrics Society.</i> 2005;53:1091-100.
Ouslander JG, Kane RL, Abrass IB. Urinary incontinence in elderly nursing home patients. <i>JAMA.</i> 1982 Sep 10;248(10):1194-8.
Ouslander JG, Maloney C, Grasela TH, Rogers L, Walawander CA. Implementation of a nursing home urinary incontinence management program with and without tolterodine. <i>Journal of the American Medical Directors Association.</i> 2001;2:207-14.
Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? <i>J Am Geriatr Soc.</i> 2011;59:1332-9.
Payne CK, Kelleher C. Redefining response in overactive bladder syndrome. <i>BJU International.</i> 2007;99:101-6.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Peters KM, MacDiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Extended-Release Tolterodine: Results From the Overactive Bladder Innovative Therapy Trial. <i>Journal of Urology</i> . 2009;182:1055-61.
Pischedda A, Farina FP, Mattana A, Deriu M, Solinas G, Bercovich E. Pelvic floor impairment and bladder instability. <i>Urogynaecologia International Journal</i> . 1999;12 BIS:127-36.
Radomski SB, Caley B, Reiz JL, Miceli PC, Harsanyi Z, Darke AC. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. <i>Current Medical Research and Opinion</i> . 2004;20:249-53.
Robbs L. Oestrogen and progestin increased urge and stress incontinence in postmenopausal women with coronary heart disease. <i>Evidence Based Nursing</i> . 2006;9(3).
Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. <i>BJU International</i> . 2006;97:1003-6.
Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. <i>The Journal of urology</i> . 2008:1034-41.
Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z. Tolterodine Extended Release Is Efficacious in Continent and Incontinent Subjects with Overactive Bladder. <i>Urology</i> . 2008;72:488-93.
Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. <i>Urology</i> . 2006:275-80.
Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. <i>BJU Int</i> . 2006;97:540-6.
Rufford J, Hextall A, Cardozo L, Khullar V. A double-blind placebo-controlled trial on the effects of 25 mg estradiol implants on the urge syndrome in postmenopausal women. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2003;14:78-83.
Salvatore S, Khullar V, Cardozo L, Milani R, Athanasiou S, Kelleher C. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. <i>Eur J Obstet Gynecol Reprod Biol</i> . 2005;119:237-41.
Salvatore S, Serati M, Digesu GA, Triacca P, Uccella S, Khullar V, et al. Efficacy of tolterodine in relation to different urodynamic findings of detrusor overactivity. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2008;19:701-4.
Salvatore S, Serati M, Ghezzi F, Uccella S, Cromi A, Bolis P. Efficacy of tolterodine in women with detrusor overactivity and anterior vaginal wall prolapse: Is it the same? <i>BJOG: An International Journal of Obstetrics and Gynaecology</i> . 2007;114:1436-8.



## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Samsioe G, Jansson I, Mellstrom D, Svanborg A. Occurrence, nature and treatment of urinary incontinence in a 70-year-old female population. <i>Maturitas</i> . 1985 Nov;7(4):335-42.
Sand PK, Davila GW, Lucente VR, Thomas H, Caramelli KE, Hoel G. Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. <i>Am J Obstet Gynecol</i> . 2012 Feb;206(2):168 e1-6.
Sand PK, Miklos J, Ritter H, Appell R. A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2004;15:243-8.
Sand PK, Morrow JD, Bavendam T, Creanga DL, Nitti VW. Efficacy and tolerability of fesoterodine in women with overactive bladder. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2009;20:827-35.
Scarpero H, Sand PK, Kelleher CJ, Berriman S, Bavendam T, Carlsson M. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. <i>Curr Med Res Opin</i> . 2011;27:921-30.
Schmidbauer CP, Chiang H, Raz S. Surgical treatment for female geriatric incontinence. <i>Clin Geriatr Med</i> . 1986 Nov;2(4):759-76.
Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is There a Synergistic Effect of Topical Oestrogens When Administered with Antimuscarinics in the Treatment of Symptomatic Detrusor Overactivity? <i>European Urology</i> . 2009;55:713-20.
Serels SR, Toglia MR, Forero-Schwanhaeuser S, He W. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. <i>Current Medical Research and Opinion</i> . 2010;26:2277-85.
Serra DB, Affrime MB, Bedigian MP, Greig G, Milosavljev S, Skerjanec A, et al. QT and QTc interval with standard and suprathreshold doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. <i>Journal of Clinical Pharmacology</i> . 2005;45:1038-47.
Shek KL, Rane A, Goh J, Dietz HP. Stress urinary incontinence after transobturator mesh for cystocele repair. <i>Int Urogynecol J Pelvic Floor Dysfunct</i> . 2009 Apr;20(4):421-5.
Siarni P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). <i>Clin Ther</i> . 2002;24:616-28.
Silva C, Silva J, Castro H, Reis F, Dinis P, Avelino A, et al. Bladder sensory desensitization decreases urinary urgency. <i>BMC Urol</i> . 2007;7:9.
Sink KM, Thomas J, rd, Xu H, Craig B, Kritchevsky S, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. <i>J Am Geriatr Soc</i> . 2008;56:847-53.
Sorbera LA, Castaner RM, Castaner J. Duloxetine oxalate: Treatment of stress urinary incontinence antidepressant norepinephrine reuptake inhibitor 5-HT reuptake inhibitor. <i>Drugs of the Future</i> . 2000;25:907-

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
16.
Stanton SL, Monga AK. Incontinence in elderly women: is periurethral collagen an advance? <i>Br J Obstet Gynaecol.</i> 1997;104:154-7.
Staskin D, Michel MC, Nitti V, Morrow JD, Wang J, Guan Z. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. <i>Current Medical Research and Opinion.</i> 2010;26:813-8.
Staskin DR, Cardozo L. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily tiroprium chloride extended release. <i>International Journal of Clinical Practice.</i> 2009;973-6.
Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. <i>International Journal of Clinical Practice.</i> 2008;62:27-38.
Staskin DR, Te AE. Short- and long-term efficacy of solifenacin treatment in patients with symptoms of mixed urinary incontinence. <i>BJU Int.</i> 2006;97:1256-61.
Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET). <i>Current Medical Research and Opinion.</i> 2002;18:177-84.
Swift S, Garely A, Dimpfl T, Payne C. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. <i>International Urogynecology Journal and Pelvic Floor Dysfunction.</i> 2003;14:50-5.
Swift SE, Siami P, Forero-Schwanhaeuser S. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study. <i>Clin Drug Investig.</i> 2009;29:305-16.
Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominaga T, Kitamura T. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. <i>Int J Urol.</i> 2006;13:15-20.
Takei M, Homma Y, Japanese Tolterodine S, Group. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. <i>International journal of urology : official journal of the Japanese Urological Association.</i> 2005:456-64.
Tanaka Y, Masumori N, Tsukamoto T. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. <i>International Journal of Urology.</i> 2010;17:796-800.
Teunissen TAM, de J, van W, Lagro-Janssen ALM. Treating urinary incontinence in the elderly--conservative measures that work: A systematic review. <i>The Journal of Family Practice.</i> 2004;53:25-32.
Thomas L, Cross S, Barrett J, French B, Leathley M, Sutton C, et al. Treatment of urinary incontinence after stroke in adults. <i>Cochrane Database of Systematic Reviews.</i> 2008.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. <i>International Urogynecology Journal and Pelvic Floor Dysfunction</i> . 2010;847-54.
Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. <i>Neurourology and Urodynamics</i> . 2009;28:47-51.
Tyagi P, Tyagi V, Chancellor M. Mirabegron: a safety review. <i>Expert Opin Drug Saf</i> 2011;10:287-94.
Ushiroyama T, Ikeda A, Ueki M. Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence: improvement in quality of life. <i>J Med</i> . 2000;31:311-9.
Van K, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder. <i>Urology</i> . 2001;57:414-21.
Van K, P E, Amarenco G, Thuroff JW, Madersbacher HG, Lock MT, et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. <i>Neurourol Urodyn</i> . 1998;17:499-512.
Van K, P E, Heesakkers J, Berriman S, Padmanabhan A, Carlsson M, et al. Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. <i>Int J Clin Pract</i> . 2010;64:584-93.
Van K, P EV, Kelleher CJ, Coyne KS, Kopp Z, Brodsky M, et al. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo. <i>Health and Quality of Life Outcomes</i> . 2009;7.
Van K. Duloxetine: An innovative approach for treating stress urinary incontinence. <i>BJU International, Supplement</i> . 2004;94:31-7.
Vardy MD, Mitcheson HD, Samuels T, Wegenke JD, Forero-Schwanhaeuser S, Marshall TS, et al. Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. <i>International Journal of Clinical Practice</i> . 2009;63:1702-14.
Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. <i>Obstetrics and Gynecology</i> . 2000:718-21.
Wada N, Watanabe M, Kita M, Osanai H, Yamaguchi S, Numata A, et al. Efficacy and safety of propiverine and solifenacin for the treatment of female patients with overactive bladder: A crossover study. <i>LUTS: Lower Urinary Tract Symptoms</i> . 2011;3:36-42.
Waetjen LE, Brown JS, Modelska K, Blackwell T, Vittinghoff E, Cummings SR, et al. Effect of raloxifene on urinary incontinence: a randomized controlled trial. <i>Obstetrics and Gynecology</i> . 2004:261-6.

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
Waetjen LE, Brown JS, Vittinghoff E, Ensrud KE, Pinkerton J, Wallace R, et al. The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women. <i>Obstet Gynecol.</i> 2005;106:946-52.
Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: A randomized placebo-controlled trial. <i>Urology.</i> 2006;68:999-1004.
Watanabe M, Yamanishi T, Honda M, Sakakibara R, Uchiyama T, Yoshida K. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder. <i>International Journal of Urology.</i> 2010;17:931-6.
Wein AJ, Khullar V, Wang JT, Guan Z. Achieving continence with antimuscarinic therapy for overactive bladder: Effects of baseline incontinence severity and bladder diary duration. <i>BJU International.</i> 2007;99:360-3.
Winkler HA, Sand PK. Treatment of detrusor instability with oxybutynin rectal suppositories. <i>Int Urogynecol J Pelvic Floor Dysfunct.</i> 1998;9:100-2.
Wiseman PA, Malone-Lee J, Rai GS. Terodiline with bladder retraining for treating detrusor instability in elderly people. <i>BMJ.</i> 1991;302:994-6.
Woodman PJ, Misko CA, Fischer JR. The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence. <i>Int Urogynecol J Pelvic Floor Dysfunct.</i> 2001;12:312-5; discussion 5.
Wyndaele J, Goldfischer ER, Morrow JD, Gong J, Tseng L, Guan Z, et al. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. <i>International Journal of Clinical Practice.</i> 2009;63:560-7.
Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Choo MS. Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. <i>BJU International.</i> 2011;107:603-11.
Yamaguchi O, Kakizaki H, Homma Y, Takeda M, Nishizawa O, Gotoh M, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. <i>Urology.</i> 2011;78:126-33.
Yokoyama T, Uematsu K, Watanabe T, Sasaki K, Kumon H, Nagai A. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. <i>Scand J Urol Nephrol.</i> 2009;43:307-14.
Zát'ura F, Vsetica J, Abadías M, Pavlík I, Schraml P, Brod'ák M, et al. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study. <i>European Urology.</i> 2010:145-52.
Zellner M, Madersbacher H, Palmtag H, Stohrer M, Bodeker RH. Trospium chloride and oxybutynin

## Exkluderade studier

Nedanstående studier har efter fulltextgranskning inte uppfyllt inklusionskriterierna och ligger således inte till grund för de evidensbaserade resultaten. En och samma studie kan ha förekommit i flera interventioner men redovisas endast en gång.

Titel
hydrochloride in a german study of adults with urinary urge incontinence: Results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. <i>Clinical Therapeutics</i> . 2009;31:2519-39.
Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. <i>The Journal of urology</i> . 2004;2311-5, quiz 435.
Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. <i>International Journal of Clinical Practice</i> . 2008;62:1664-74.
Zinner N, Noe L, Rasouliyan L, Marshall T, Runken MC, Seifeldin R. Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis. <i>Am J Geriatr Pharmacother</i> . 2009;7:373-82.
Zinner N, Susset J, Gittelman M, Arguinoniz M, Reveda L, Haab F. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. <i>Int J Clin Pract</i> . 2006;60:119-26.
Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. <i>World J Urol</i> . 2005;23:248-52.
Zorzitto ML, Holliday PJ, Jewett MA, Herschorn S, Fernie GR. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. <i>Age Ageing</i> . [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Review]. 1989 May;18(3):195-200.
Zullo MA, Ruggiero A, Montera R, Plotti F, Muzii L, Angioli R, et al. An ultra-miniinvasive treatment for stress urinary incontinence in complicated older patients. <i>Maturitas</i> . 2010;65:292-5.
Wang PS, Levin R, Zhao SZ, Avorn J. Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. <i>Journal of the American Geriatrics Society</i> . 2002;50:117-24.